15 minutes
The global pandemic has charged us to do things differently. We have seen unprecedented levels of collaboration, increased use of technology in various ways, and speeds of delivery we would never have thought possible. How do we capture these “silver linings” and learn from these experiences beyond COVID-19 to create a paradigm shift in how we do global drug development work?


Shoibal Datta - Head, R&D Digital Strategy Group, Data Sciences Institute, Takeda